Figure 5
Recombinant IL-22 induced more severe pulmonary inflammation than recombinant IL-17.
(A) The expression of IL-17 and IL-22 mRNA in LPS-challenged mice at D2. *p < 0.05, compared with the expression of IL-17. (B) Total inflammatory cells and neutrophils in the BALF of the mice treated with recombinant cytokines. *p < 0.05, compared with the PBS-treated group, #p < 0.05, compared with the rIL-17-treated group. (C) The histopathological findings demonstrated severe neutrophils infiltrated in rIL-22 treated mice (HE: ×400). (D) CXCLs amplification in qPCR in WT mice treated with recombinant cytokines. *p < 0.05, compared with the PBS-treated group. (E) Recombinant IL-22 increased the phosphorylation level of STAT3. Mice treated with recombinant cytokines (B–E) were harvested on D1. The error bars indicate SEM. All mice were wild type, with 3~6 mice per group.
